Mortality for 10 and up to 13 years of follow up. Patients who continued after the dose finding phase (phase 1) are considered as full trial patients. Those who did not complete this are listed as phase 1 incomplete. An additional 13 patients considered to have atypical Parkinsonism before 5 years are excluded
| Full trial patients n (%) | Phase 1 incomplete n (%) | Total n (%) | |
|---|---|---|---|
| Total No considered | 126 | 10 | 136 |
| Alive at 10 years | 76 (60) | 4 (40) | 80 (59) |
| Death before 10 years | 46 (36) | 4 (40) | 50 (37) |
| Lost to follow up at 10 years | 4 (3) | 2 (20) | 6 (4) |
| Accounted for at 10 years | 122 (97) | 8 (80) | 130 (96) |
| Death after 10 years | 13 | 0 | 13 |
| Total deaths up to 13 years | 59 (47) | 4 (40) | 63 (46) |